At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
I-131 Tositumomab therapeutic regimendrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Jun 11, 2007·Updated Aug 1, 2018
In Brief
A Phase 2 clinical trial evaluating I-131 Tositumomab therapeutic regimen for Hodgkin's Disease. Completed, enrolled 12 participants across 1 site.
Detailed Summary
The purpose of this study is to find the highest safe dose of Iodine-131 Tositumomab (Bexxar®) that can be given to patients who have relapsed/refractory Hodgkin's lymphoma, what side effects these patients get when they take Bexxar® and if Bexxar® is effective in treating relapsed/refractory Hodgkin's lymphoma. Bexxar® works by delivering doses of radiation to cancer cells.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHodgkin's Disease
CountriesUnited States
CollaboratorsGlaxoSmithKline
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2007
First PostedJun 2007
Primary CompletionJan 2014
Study CompletionNov 2015
TodayJul 2026
First PostedJun 11, 2007
Enrollment StartJun 1, 2007
Primary CompletionJan 1, 2014
Study CompletionNov 1, 2015
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 19.1 years ago
Interventions
I-131 Tositumomab therapeutic regimendrug
Tositumomab and I-131 tositumomab are given intravenously. A test dose is given followed by a larger treatment dose.